Fig. 7.
Graphs showing the effect of ibandronate treatment (4 μg per mouse per day) on (A) hindlimb paralysis and (B) survival in 5TGM1 myeloma-bearing mice. Significant differences were not observed between myeloma-bearing mice treated with PBS or with ibandronate.